Medizinische Universit├Ąt Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Fuereder, T; Berghoff, AS; Heller, G; Haslacher, H; Perkmann, T; Strassl, R; Berger, JM; Puhr, HC; Kreminger, J; Moik, F; Schubert, L; Starzer, AM; Steindl, A; Winkler, S; Preusser, M; Tobudic, S.
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
ESMO Open. 2020; 5(5):e000889 Doi: 10.1136/esmoopen-2020-000889 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-authors Med Uni Graz
Moik Florian
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care. METHODS: HCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay. Reactive samples were confirmed or disproved by the Abbott SARS-CoV-2 IgG test. Additionally, a structured questionnaire regarding basic demographic parameters, travel history and COVID-19-associated symptoms had to be completed by HCP. RESULTS: 146 subjects (62 HCP and 84 patients with cancer) were enrolled. In the oncological HCP cohort, 20 (32.3%) subjects were medical oncologists, 28 (45.2%) nurses at our ward and 14 (22.6%) fulfil other functions such as study coordinators. In the patient cohort, most individuals are on active anticancer treatment (96.4%). 26% of the HCP and 6% of the patients had symptoms potentially associated with COVID-19 since the end of February 2020. However, only in 2 (3.2%) HCP and in 3 (3.6%) patients, anti-SARS-Cov-2 total antibodies were detected. The second assay for anti-SARS-Cov-2 IgG antibodies confirmed the positive result in all HCP and in 2 (2.4%) patients, suggesting an initial assay's unspecific reaction in one case. In individuals with a confirmed test result, an active COVID-19 infection was documented by a positive SARS-CoV-2 RNA PCR test. CONCLUSION: Specific anti-SARS-CoV-2 antibodies were found solely in persons after a documented SARS-CoV-2 viral infection, thus supporting the test methods' high sensitivity and specificity. The low prevalence of anti-SARS-CoV-2 antibodies in our cohorts indicates a lack of immunity against SARS-CoV-2. It highlights the need for continued strict safety measures to prevent uncontrolled viral spread among oncological HCPs and patients with cancer.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent - administration & dosage
Adult - administration & dosage
Aged - administration & dosage
Aged, 80 and over - administration & dosage
Antibodies, Viral - blood
Austria - epidemiology
Betacoronavirus - immunology, pathogenicity
Biomarkers - blood
COVID-19 - administration & dosage
COVID-19 Testing - administration & dosage
Clinical Laboratory Techniques - administration & dosage
Coronavirus Infections - diagnosis, epidemiology, transmission, virology
Female - administration & dosage
Host-Pathogen Interactions - administration & dosage
Humans - administration & dosage
Male - administration & dosage
Medical Staff, Hospital - administration & dosage
Middle Aged - administration & dosage
Nursing Staff, Hospital - administration & dosage
Oncologists - administration & dosage
Oncology Nursing - administration & dosage
Oncology Service, Hospital - administration & dosage
Pandemics - administration & dosage
Patients - administration & dosage
Pneumonia, Viral - diagnosis, epidemiology, transmission, virology
Predictive Value of Tests - administration & dosage
Prospective Studies - administration & dosage
Reproducibility of Results - administration & dosage
Retrospective Studies - administration & dosage
SARS-CoV-2 - administration & dosage
Seroepidemiologic Studies - administration & dosage
Serologic Tests - administration & dosage
Tertiary Care Centers - administration & dosage
Young Adult - administration & dosage

Find related publications in this database (Keywords)
seroprevalence
SARS-COV-2
healthcare professionals
COVID-19
© Med Uni GrazImprint